Related Experiment Video
Updated: May 12, 2026
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation
Seyedeh Negin Kassaee1, Derek Richard2, Godwin A Ayoko3
1School of Clinical Sciences, Queensland University of Technology (QUT), Brisbane, QLD QLD4001, Australia.
Abstract:
Lung cancer is a leading cause of global cancer mortality, often treated with chemotherapeutic agents. However, conventional approaches such as oral or intravenous administration of drugs yield low bioavailability and adverse effects. Nanotechnology has unlocked new gateways for delivering medicine to their target sites. Lipid-polymer hybrid nanoparticles (LPHNPs) are one of the nano-scaled delivery platforms that have been studied to exploit advantages of liposomes and polymers, enhancing stability, drug loading, biocompatibility and controlled release. Pulmonary administration of drug-loaded LPHNPs enables direct lung deposition, rapid onset of action and heightened efficacy at low doses of drugs. In this manuscript, we will review the potential of LPHNPs in management of lung cancer through pulmonary administration.
Insights
Lipid-polymer hybrid nanoparticles offer a promising approach for lung cancer treatment. Pulmonary delivery of these nanoparticles enhances drug efficacy and reduces side effects compared to traditional methods.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Lung cancer remains a significant global health challenge, with conventional chemotherapy facing limitations like poor bioavailability and adverse effects.
- Nanotechnology offers innovative solutions for targeted drug delivery, overcoming barriers associated with traditional administration routes.
- Lipid-polymer hybrid nanoparticles (LPHNPs) combine the benefits of liposomes and polymers for improved drug delivery systems.
Purpose of the Study:
- To review the potential of pulmonary administration of lipid-polymer hybrid nanoparticles (LPHNPs) for lung cancer management.
- To highlight the advantages of LPHNPs in enhancing drug delivery and therapeutic outcomes in lung cancer.
- To explore the role of nanotechnology in advancing lung cancer treatment strategies.
Main Methods:
- Review of existing literature on lipid-polymer hybrid nanoparticles (LPHNPs) for drug delivery.
- Analysis of studies focusing on pulmonary administration routes for nanomedicines.
- Evaluation of the characteristics and performance of LPHNPs in preclinical and clinical settings for lung cancer.
Main Results:
- Pulmonary administration of drug-loaded LPHNPs facilitates direct deposition in the lungs.
- LPHNPs demonstrate enhanced stability, drug loading capacity, and controlled release properties.
- This approach can lead to a rapid onset of action and improved efficacy at reduced drug dosages.
Conclusions:
- Lipid-polymer hybrid nanoparticles (LPHNPs) represent a promising nanocarrier system for pulmonary drug delivery in lung cancer treatment.
- Pulmonary administration of LPHNPs offers a viable strategy to improve therapeutic efficacy and minimize systemic toxicity.
- Further research into LPHNPs holds significant potential for advancing the management of lung cancer.
